Hisamitsu, Nippon Shinyaku Conclude Joint Development

Hisamitsu Pharmaceutical and Nippon Shinyaku announced on April 7 that they have entered into a joint development agreement for HFT-290, a drug candidate for the treatment of cancer pain. The two companies will conduct Phase III clinical trials, and co-promote the new product in Japan. HFT-290 is a fentanyl citrate plaster developed based on Hisamitsu's proprietary technology, Transdermal Drug Delivery System. With a once-a-day dosage, the drug can achieve stable pain control.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9804)